An interventional study of Remote Monitoring Program in Obesity & Overweight, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Stanford University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Obesity by Stanford University — 8 open to participants now, 10 under way, none of them phase 3. Obesity · Stanford University.
Among the 61 studies in Obesity by Stanford University, this one is the 25th largest by planned enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2026, is one of 42 with no phase, and was the 59th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →8 of the 61 studies in Obesity by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 10–15
Stanford University · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Stanford University · Sites in United States
Ages 18–70 · Healthy volunteers
Stanford University · Sites in United States
Ages 35–65 · Healthy volunteers
Stanford University · Sites in United States
Ages 30–65 · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 10 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 2 · Phase 4 1
First in 1982; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 102 across the 53 interventional studies, 115 across the 4 observational. Of the 47 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
2 of the studies in Obesity by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT07032571Stanford UniversityReset: Enhancing Weight Loss in a Digital Intervention | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 61 studies in Obesity by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will develop a simple index to measure how well the body uses insulin and overall heart and metabolic health in children and teens with obesity. The investigators will use data from wearable devices (like fitness trackers) and glucose monitors, along with lab tests, to learn how activity and glucose relate to metabolic problems.
This is a prospective cohort study to develop a metabolic index for insulin sensitivity and cardiometabolic fitness among children and adolescents with obesity. Adolescent patients undergoing evaluation for bariatric surgery or medical management of wight using GLP-1 agonist therapies will be consented for participation. Participants will be given a wearable fitness device and a continuous glucose monitor. Continuous monitoring will be carried out at three time points: preoperative or prior to starting medication, perioperative or after 3-4 weeks of GLP1 use during early treatment phase, and 3 months post-operatively or 3 months after dose stabilization or discontinuation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adolescent patients in the Adolescent Bariatric Program at Stanford Children's undergoing bariatric surgery will undergo continuous glucose monitoring and fitness tracking throughout the course of study.
Other: Remote Monitoring Program
Adolescent patients being considered for GLP-1 receptor agonist therapy for obesity management will undergo continuous glucose monitoring and fitness tracking throughout the course of study.
Other: Remote Monitoring Program
Continuous glucose monitors will be placed at 2 or 3 clinically relevant time points and participants will track their fitness using wearable devices.
Percent Reduction in BMI
assessment of change in BMI from pre-intervention to post-intervention
Time frame: baseline through study completion, an average of 4 months
Body Weight
Change in body weight (kg)
Time frame: baseline through study completion, an average of 4 months
Fasting Glucose
change in fasting glucose levels from pre-intervention to post-intervention
Time frame: baseline through study completion, an average of 4 months
Fasting Insulin
change in fasting insulin levels from pre-intervention to post-intervention
Time frame: baseline through study completion, an average of 4 months
HbA1c
change in HbA1c levels from pre-intervention to post-intervention
Time frame: baseline through study completion, an average of 4 months
Lipid Panel
changes in lipid panel levels from pre-intervention to post-intervention
Time frame: baseline through study completion, an average of 4 months
Liver Enzymes
changes in liver enzymes from pre-intervention to post-intervention
Time frame: baseline through study completion, an average of 4 months
Obesity-related Comorbidities
Defined as resolution or improvement according to prespecified clinical criteria
Time frame: baseline through study completion, an average of 4 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Dec 2030, 59 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 59 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.